

# Specialty Guideline Management

## Piqray

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Piqray	alpelisib

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indications<sup>1</sup>

Piqray is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

#### Compendial Uses<sup>2</sup>

Breast cancer: Therapy for recurrent HR-positive, HER2-negative, PIK3CA mutated disease

All other indications are considered experimental/investigational and not medically necessary.

### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Piqray SGM 3089-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
3089-A

- Documentation of test confirming presence of PIK3CA mutation
- Documentation of HR and HER2 status

## Coverage Criteria

### Breast Cancer<sup>1-2</sup>

Authorization of 12 months may be granted for treatment of HR-positive, HER2-negative, PIK3CA-mutated recurrent, advanced or metastatic breast cancer when all of the following criteria are met:

- The requested drug is used in combination with fulvestrant
- Disease has progressed while on or after an endocrine-based regimen

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

## References

1. Piqray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2024.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed November 6, 2024.